196 - New Antimicrobials in the Pipeline Part 2

Saturday, October 14, 2023

8:00 AM - 9:00 AM US ET

Location: 205 ABC

CE: No CE Credit Offered

All relevant financial disclosures have been mitigated.

Moderator(s)

Twisha Patel, PharmD, BCIDP (she/her/hers)

Subject Matter Expert / Infectious Diseases Pharmacist, International Infection Control Branch
Centers for Disease Control and Prevention
Atlanta, GA, United States
Michael Boeckh, MD PhD

Professor
Internal Medicine
Fred Hutchinson Cancer Center
Seattle, WA, United States

Disclosure(s):

Twisha S. Patel, PharmD, BCIDP: No financial relationships to disclose

Michael J. Boeckh, MD PhD: Allovir: Advisor/Consultant (Ongoing); Ansun Biopharma: Grant/Research Support (Ongoing); EvrysBio: Advisor/Consultant (Ongoing), Ownership Interest (Ongoing); GlaxoSmithKline: Grant/Research Support (Ongoing); Helocyte: Advisor/Consultant (Ongoing); Merck: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Moderna: Advisor/Consultant (Ongoing); Symbio: Advisor/Consultant (Ongoing); Vir Biotechnology: Advisor/Consultant (Ongoing)

Presentations:

8:00 AM - 8:12 AM US ET

PC945 (OPELCONAZOLE) NEBULIZER SUSPENSION - a new inhaled antifungal in development for pulmonary aspergillosis
Speaker: Lance Berman, MB.ChB (he/him/his) – Pulmocide Ltd
8:12 AM - 8:24 AM US ET

Helicase-primase inhibitor pritelivir for the treatment of resistant HSV infections in immunocompromised patients
Speaker: Alexander Birkmann, PhD (he/him/his) – AiCuris Anti-Infective Cures AG
8:24 AM - 8:36 AM US ET

Ceftibuten-ledaborbactam, an oral beta-lactam / beta-lactamase inhibitor
Speaker: Paul McGovern, MD – Venatorx Pharmaceuticals
8:36 AM - 8:48 AM US ET

Discovery and characterization of Zosurabalpin (RG6006), a Tethered Macrocyclic Peptide Targeting Acinetobacter baumannii
Speaker: William Stubbings, PhD (he/him/his) – F. Hoffmann-La Roche Ltd
8:48 AM - 9:00 AM US ET

A Fully Human IgG Monoclonal Antibody (MAb) to the Microbial Surface Polysaccharide PNAG (Poly N-Acetyl Glucosamine): A Pathway for the Development of a Broad-Spectrum Antibody Therapeutic by Alopexx, Inc.
Speaker: Daniel Vlock, MD (he/him/his) – Alopexx, Inc.